IORT-Breast at MCNH
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Breast Cancer - Female
- Early Stage Breast Cancer
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 55 years and 125 years
- Gender
- Only males
Description
Objectives: (primary and important secondary objectives) The primary objective is to determine rates of recurrence at 5, and 10 years following IORT-Breast at Navicent Health. Secondary objectives include determination of acute and late effects of IORT-Breast at the treatment site, cosmetic outcomes...
Objectives: (primary and important secondary objectives) The primary objective is to determine rates of recurrence at 5, and 10 years following IORT-Breast at Navicent Health. Secondary objectives include determination of acute and late effects of IORT-Breast at the treatment site, cosmetic outcomes and satisfaction over 10 years. In addition, the study will determine why patients who were scheduled for IORT-Breast did not receive it after lumpectomy. Study Design: Prospective, observational registry. Setting/Participants: The study focuses on outpatients/short stay surgery performed at the Medical Center, Navicent Health, Macon, GA only. Participants have been deemed eligible for IORT-Breast or have received IORT-Breast within the last 6 months. Key eligibility criteria for IORT- Breast includes women, aged 55 years old or greater, diagnosed with clinically node negative, grade 1 or 2 Invasive Breast Cancer with no lymphovascular invasion, that is 20mm or less in greatest dimension, Estrogen Receptor (ER) positive, HER 2 Neu Negative, and with a depth greater than 10mm from skin. Study Interventions and Measures: Participants will be eligible for IORT-Breast or have received IORT-Breast in the previous 6 months. Participants who were scheduled for IORT-Breast and do not receive IORT-Breast will have reasons for not receiving IORT-Breast recorded and will not be followed further. Participants receiving IORT-Breast will have treatment parameters recorded and will be followed every 6 months for 2 years and then annually until up to 10 years following treatment.
Tracking Information
- NCT #
- NCT04595435
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Paul Dale, MD Navicen Health Physician's Group Principal Investigator: David Cole, MD Central Georgia Radiation Oncology